Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
E.E.S. 400 vs TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.
Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.
Treatment of infections caused by susceptible strains of microorganisms: respiratory tract infections (including Legionnaires disease, pertussis), skin and soft tissue infections, diphtheria, syphilis, chlamydial infections, and ocular infections in neonates.,Prophylaxis of recurrent rheumatic fever.,Off-label: gastrointestinal motility disorder (as a motilin agonist).
Moderate to severe vasomotor symptoms due to menopause (estradiol component, off-label for testosterone),Male hypogonadism (testosterone component)
Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.
Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.
1.5-2.0 hours in adults with normal renal function; may be prolonged in hepatic impairment (up to 5-6 hours) but not significantly changed in renal disease.
Testosterone cypionate: approximately 8 days; estradiol cypionate: approximately 8-10 days. Clinical context: steady-state reached in 3-5 weeks.
Primarily metabolized in the liver via demethylation by CYP3A4; undergoes N-demethylation and hydroxylation.
Testosterone cypionate: Hydrolyzed to testosterone then metabolized primarily in the liver via oxidation (CYP3A4, CYP2C9) and conjugation; estradiol cypionate: Hydrolyzed to estradiol then metabolized via hydroxylation (CYP1A2, CYP3A4) and glucuronidation.
Primarily hepatic (biliary) excretion of unchanged drug and metabolites; approximately 2-5% renal excretion of unchanged drug; 5-15% fecal elimination.
Renal (90% as glucuronide and sulfate conjugates, less than 5% as unchanged drug); fecal (approximately 10%).
70-80% bound to albumin; binding is reversible and saturable at high concentrations.
Testosterone: 97-99% bound to sex hormone-binding globulin (SHBG) and albumin; estradiol: 98% bound to SHBG and albumin.
Approximately 0.7 L/kg (range 0.5-0.9 L/kg); indicates extensive tissue penetration including intracellular and inflammatory fluids.
Testosterone: approximately 0.6 L/kg; estradiol: approximately 0.5 L/kg. Indicates distribution into peripheral tissues.
Oral (as erythromycin ethylsuccinate): approximately 30-65% (variable, reduced by food); intravenous: 100%.
Intramuscular: approximately 100% due to slow release from oil depot; no oral bioavailability (hepatic first-pass inactivation).
No specific dose adjustment required for renal impairment; caution with high doses in severe renal failure (Cr Cl <10 m L/min) due to potential ototoxicity.
No specific dose adjustment recommended; use with caution in severe impairment due to limited data.
In hepatic impairment, reduce dose by 50-75% depending on severity. Child-Pugh Class A: no adjustment; Class B: reduce to 50% of normal dose; Class C: avoid or use with extreme caution, maximum 1 g per day.
Contraindicated in severe hepatic impairment (Child-Pugh C). For mild to moderate (Child-Pugh A or B), use with caution and monitor hepatic function.
30-50 mg/kg/day in 4 divided doses. For severe infections, up to 60-100 mg/kg/day. Maximum 2 g/day.
Not recommended for pediatric use; safety and efficacy not established.
No specific dose adjustment; monitor for QT prolongation and hearing loss. Consider lower end of dosing range due to age-related decline in hepatic function.
Use lower end of dosing range (e.g., testosterone cypionate 50-100 mg with estradiol cypionate 2-5 mg every 4 weeks) due to increased risk of cardiovascular and prostate adverse effects; monitor closely.
Increased risk of infantile hypertrophic pyloric stenosis (IHPS) when given to neonates. Erythromycin has also been associated with prolongation of the QT interval and risk of cardiac arrhythmias, including torsades de pointes.
Estrogens, with or without progestins, should not be used for the prevention of cardiovascular disease or dementia. Increased risks of endometrial cancer, stroke, and deep vein thrombosis. Venous thromboembolism risk is increased with estrogen-containing products.
Hepatic dysfunction, QT prolongation (risk of arrhythmia), exacerbation of myasthenia gravis, Clostridioides difficile-associated diarrhea, ototoxicity (especially with high doses or renal impairment), potential for drug interactions (CYP3A4 inhibitors/inducers).
Cardiovascular risk: increased risk of myocardial infarction, stroke, venous thromboembolism,Endometrial cancer: unopposed estrogen use increases risk,Breast cancer: caution in patients with known or suspected estrogen-dependent tumors,Hepatic impairment: dose adjustment may be needed,Hypercalcemia: caution in patients with bone metastases,Fluid retention: caution in cardiac or renal dysfunction
Hypersensitivity to erythromycin or any macrolide antibiotic, concomitant use with terfenadine, astemizole, cisapride, pimozide, ergotamine, or dihydroergotamine (risk of cardiac arrhythmias).
Pregnancy (estrogen component),Breast cancer (known, suspected, or history, unless appropriate indication),Estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Active thromboembolic disease or history of thromboembolism (e.g., DVT, PE),Known hypersensitivity to components,Men with prostate or breast cancer (testosterone component)
Take with food to minimize gastrointestinal upset. Avoid grapefruit juice as it can increase erythromycin concentrations via CYP3A4 inhibition. No other significant food interactions.
Avoid excessive grapefruit juice as it may affect hormone metabolism. No specific food interactions; maintain a balanced diet.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human studies in first trimester. No known risk of major birth defects or miscarriage. Avoid in maternal myasthenia gravis due to potential neonatal hypotonia.
First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalities. Third trimester: Possible advanced bone age and growth acceleration. Not recommended in any trimester.
Compatible with breastfeeding. Erythromycin is excreted into breast milk in small amounts (M/P ratio approximately 0.5). No adverse effects reported in infants. Monitor infant for gastrointestinal disturbances or rash.
Contraindicated during breast-feeding. Excreted in breast milk, may cause masculinization of female infant. M/P ratio not known.
No dose adjustment required. Physiologic changes in pregnancy (increased volume of distribution, renal clearance) do not necessitate dose changes for erythromycin. Standard adult dosing applies.
Not recommended for use during pregnancy; dose adjustment is not applicable.
E. E. S. 400 (erythromycin ethylsuccinate) is a macrolide antibiotic with bacteriostatic activity. It is a prodrug hydrolyzed to erythromycin base. Use with caution in patients with hepatic impairment or preexisting hearing loss. Monitor for QT prolongation, especially with concurrent use of other QT-prolonging drugs. Commonly used as an alternative in penicillin-allergic patients for respiratory tract infections. It also has prokinetic effects on the GI tract, which can be utilized in gastroparesis but may cause abdominal cramping.
Monitor for signs of thromboembolism, especially in patients with risk factors. Measure serum testosterone and estradiol levels periodically to maintain therapeutic range. Use with caution in patients with history of myocardial infarction or stroke. Contraindicated in men with breast or prostate cancer. May cause gynecomastia and fluid retention.
Take this medication exactly as prescribed, usually every 6 hours or as directed.,Complete the full course even if you feel better to prevent resistance.,May cause stomach upset; taking with food can reduce GI irritation.,Avoid grapefruit juice as it may affect drug levels.,Report symptoms of liver problems (yellowing skin/eyes, dark urine) or hearing loss immediately.,Do not take with certain medications like statins or warfarin without consulting your doctor.,Use effective contraception if applicable, as erythromycin may reduce birth control pill efficacy.
Report any signs of blood clots (leg pain, chest pain, shortness of breath) immediately.,Do not use if you are pregnant or breastfeeding.,Regular blood tests are required to monitor hormone levels and liver function.,Use as prescribed; do not adjust dose without consulting your healthcare provider.,Inform your doctor about all medications you are taking, including over-the-counter drugs.
No interactions on record
"Estradiol (estrogen) may reduce the anticoagulant effect of warfarin, likely by enhancing the synthesis of clotting factors (e.g., factors II, VII, IX, X) in the liver. This interaction can lead to a decrease in the International Normalized Ratio (INR) and potentially increase the risk of thromboembolic events. Conversely, when estradiol is discontinued, warfarin's effect may increase, raising the risk of bleeding."
"Acitretin, a retinoid used for psoriasis, induces CYP3A4 enzymes, accelerating estradiol metabolism and reducing its systemic exposure. This can lead to decreased contraceptive efficacy of estrogen-containing oral contraceptives, potentially resulting in unplanned pregnancy. Additionally, acitretin itself is teratogenic, making effective contraception critical during therapy."
"The combination of Halcinonide, a potent topical corticosteroid, with Estradiol may lead to increased systemic absorption of Estradiol due to corticosteroid-induced inhibition of estrogen metabolism via competition for cytochrome P450 enzymes, particularly CYP3A4. This interaction can result in elevated estradiol serum concentrations, potentially augmenting estrogenic effects such as thromboembolic risk, endometrial hyperplasia, and hormonal imbalance. Clinically, patients may experience symptoms like breakthrough bleeding, breast tenderness, or worsened side effects of estrogen therapy."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about E.E.S. 400 vs TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE, answered by our medical review team.
E.E.S. 400 is a Macrolide Antibiotic that works by Erythromycin, a macrolide antibiotic, binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis. At high concentrations, it may also inhibit RNA synthesis.. TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is a Androgen that works by Testosterone cypionate is a prodrug of testosterone, which binds to androgen receptors and modulates gene expression, promoting male secondary sex characteristics and anabolic effects. Estradiol cypionate is a prodrug of estradiol, which binds to estrogen receptors and regulates gene transcription involved in female reproductive development and maintenance.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between E.E.S. 400 and TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of E.E.S. 400 is: Erythromycin ethylsuccinate 400 mg orally every 6 hours. For severe infections, up to 4 g/day in divided doses.. The standard adult dose of TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is: Testosterone cypionate 50-200 mg and estradiol cypionate 2-10 mg intramuscularly every 2-4 weeks.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between E.E.S. 400 and TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. E.E.S. 400 is classified as Category C. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies; inadequate human studies in first trimester. No known risk of major birth defects or miscarriage. Avoid i. TESTOSTERONE CYPIONATE-ESTRADIOL CYPIONATE is classified as Category D/X. First trimester: High risk of masculinization of female fetus. Second trimester: Androgenic effects may cause clitoral enlargement, labial fusion, and urogenital sinus abnormalitie. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.